Sales Marketing
Resume:
ANDRIS ORTMANIS
Morristown, New Jersey, 07960
Telephone: 908-***-**** Email: *********@*******.***
SUMMARY
A leader to drive the growth of an established or emerging pharmaceutical franchise, leveraging extensive commercial
expertise and achievement in progressively more senior US and Global roles. Proven success in defining objectives and in
developing and executing highly effective strategies to achieve a business vision through productive internal and external
relationships. Create and lead efficient, results oriented multifunctional teams to integrate product portfolios, to launch new
drugs and new indications, and to drive value through to the end of a product’s life cycle. Undergraduate and graduate
degrees in biochemistry, engineering, and business administration underscore broad oncology (chemotherapy and
immunotherapy) and infectious disease marketing, sales and business development experience.
PROFESSIONAL EXPERIENCE
sanofi aventis, Bridgewater, New Jersey, USA 2001 – 2010
sanofi aventis is a world leader in drug development and sales and marketing in oncology, diabetes, cardiovascular,
thrombosis, central nervous system, internal medicine, and vaccines therapeutic areas.
Senior Marketing Director, Iniparib / BSI 201 (2009 – 2010)
sanofi aventis USA, Oncology Sales and Marketing
Lead cross functional Iniparib Commercialization Team. Developed iniparib launch plan through identifying, prioritizing,
and aligning pre launch objectives and workstreams across Marketing, Sales, Medical Affairs, Field Medical, R&D,
Regulatory, Finance, Legal and Industrial Operations project subteams in support of anticipated 2011 approval and launch.
Bridge the sanofi aventis commercial relationship with BiPar Sciences, the biotech company from which this first in class
PARP inhibitor was acquired. Iniparib is the lead sanofi aventis oncology pipeline agent.
Marketing Director, Taxotere® Oncology Sales and Marketing (2005 – 2009)
sanofi aventis USA, Oncology Sales and Marketing
Led US breast cancer marketing team. Developed brand objectives, strategies and marketing programs to drive Taxotere ®
breast cancer and gastric cancer sales growth and market position. Led cross functional teams to integrate sales, channel
marketing, medical, medical communications, regulatory and pharmacoeconomic programs into brand strategy. Assessed
franchise pipeline and potential new product in licensing opportunities.
• Launched adjuvant breast cancer Herceptin® Taxotere® indication in 2008 in partnership with Genentech (Roche)
• Achieved taxane class leadership by growing Taxotere® adjuvant share three fold since 2005 while maintaining leading
metastatic breast cancer position
• Taxotere® is approved for the treatment of breast, lung, prostate, gastric and head & neck cancers in more than 100
countries worldwide. Taxotere® global revenues exceeded € 2.0 billion in 2009.
Global Marketing Director, Taxotere®
Global Marketing and Medical Department (Oncology) (2001 – 2005)
Developed global Taxotere® brand objectives, strategies and marketing platform for metastatic and adjuvant breast cancer
indications, and implemented these through worldwide affiliates.
• Launched adjuvant breast cancer indication through US and European affiliates in 2004
• Launched Taxotere capecitabine (MBC) in 2003 and Taxotere trastuzumab (MBC) in 2004 exUS.
• Led global product life cycle strategy planning
• Developed and implemented new and globally consistent marketing campaign.
Sanofi Pasteur Limited, Toronto, Canada (formerly Aventis Pasteur) 1987 – 2001
Leading international manufacturer of vaccines, and other health care biologicals.
Head, Oncology Marketing (1998 – 2001)
Head of strategy and marketing for marketed and in house R&D immunotherapy based oncology products, and business
development programs. Directed the global ImmuCyst® oncology marketing team and the commercial infrastructure to
support global sales. ImmuCyst® (TheraCys® in US) is approved for the treatment of superficial bladder cancer in more
than 50 countries worldwide.
• Developed, signed and implemented a Joint Development Agreement with Nippon Kayaku, a Japanese pharmaceutical
company, leading to the approval and launch of ImmuCys® in Japan
• Commercial lead for immunotherapy based oncology research and development platform
ANDRIS ORTMANIS
Page 2
Telephone: 908-***-**** Email: *********@*******.***
ImmuCyst® Business Manager, Oncology Business Unit (1995 – 1998)
Directed uro oncology Sales and Marketing Team for ImmuCyst ®. Prioritized corporate Regulatory, Clinical and Medical,
and R&D activities to support commercial strategies.
• Launched ImmuCyst® in more than 30 countries, including Argentina, Australia, Austria, France, Hong Kong, Israel,
Italy, Korea, Malaysia, New Zealand, Portugal, Switzerland, Taiwan, Thailand, and Turkey.
• Established European ImmuCyst® distributor network through third party pharmaceutical company partners
• Established and directed ImmuCyst® Sales and Marketing commercial operations in Canada and Europe.
• Recruited Medical Director and established European based Medical Office
Marketing Manager, Marketing & Business Development Division (1992 – 1994)
Directed the international adult and pediatric vaccines marketing department. Responsible for ImmuCyst ® sales and
marketing and uro oncology business development.
• Developed and implemented global marketing strategy and commercial platform for ImmuCyst ®
• Directed Canadian ImmuCyst® sales team
Senior Product Manager, International Division (1989 – 1992)
Responsible to develop international markets for ProHIBiT®, a vaccine to protect infants against bacterial meningitis caused
by Haemophilus influenzae type b.
• Launched ProHIBiT® in Germany, Switzerland, Austria, Australia, Korea, and Argentina
• Received 1992 Canada Award for Business Excellence for Marketing of ProHIBiT®
• Established ProHIBiT® in three European National Immunization Programs
• Developed and implemented global ProHIBiT® marketing platform.
Product Manager, International Division (1988 – 1989)
Responsibility for Diphtheria, Pertussis and Tetanus Vaccines Product Group.
• Managed UNICEF/PAHO vaccine contracts
• Grew profitability by diversifying customer base to include veterinary/animal health customers
Research and Development Engineer, Bacterial Vaccine Pilot Plant (1987)
Optimized filtration unit operations for the primary recovery of bacterial antigens from production scale pertussis vaccine
fermentation process
Weston Research Centre (Diversified Research Limited), Toronto Canada 1985 – 1986
The Weston Research Centre serves George Weston Limited, which conducts food processing, food distribution and resource
based operations in North America.
Engineer, Biotechnology Division (1985 1986)
Directed research teams to development, scale up, and implement fermentation processes and other technologies into
commercial food and resource processing operations. Evaluated technological and financial feasibility of adopting new
technology, production expansion, or equipment upgrades to existing production processes.
ACADEMIC BACKGROUND
Master of Business Administration (MBA), Richard Ivey School of Business,
University of Western Ontario, 1988
Master of Engineering (Chemical), McGill University, 1986
Bachelor of Engineering (Chemical), McGill University, 1983
Bachelor of Science (Biochemistry), McGill University, 1980
Contact this candidate